financetom
Business
financetom
/
Business
/
Market Chatter: Occidental Petroleum Issues $5 Billion in Bonds to Finance CrownRock Purchase
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Occidental Petroleum Issues $5 Billion in Bonds to Finance CrownRock Purchase
Jul 23, 2024 12:47 PM

03:01 PM EDT, 07/23/2024 (MT Newswires) -- Occidental Petroleum ( OXY ) is selling investment-grade bonds for $5 billion to finance the acquisition of CrownRock and the bonds will be sold in five parts, Bloomberg reported Tuesday, citing a person with knowledge of the matter.

The longest offering extends over 30 years with a yield of 160 basis points above Treasuries, the person was quoted as saying.

The bond offering is not subject to completion of the CrownRock acquisition, however, Occidental will repurchase the outstanding notes at 101 cents on the dollar if the transaction is not completed by Dec. 10, 2025, the report added, citing the person.

Occidental did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 60.28, Change: -0.93, Percent Change: -1.52

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Eliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines Deal
Eliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines Deal
Apr 11, 2024
Eliem Therapeutics Inc ( ELYM ) has agreed to acquire Tenet Medicines Inc., a development-stage private biotechnology company.  The combined company plans to focus on advancing TNT119, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. In June 2023, Eliem Therapeutics ( ELYM ) completed a review of its business, including the...
Market Chatter: Amazon Looking to Invest in UK Tech Startups With Innovation Fund
Market Chatter: Amazon Looking to Invest in UK Tech Startups With Innovation Fund
Apr 11, 2024
12:41 PM EDT, 04/11/2024 (MT Newswires) -- Amazon.com ( AMZN ) is in active conversations for possible funding support for UK-based technology startups via the e-commerce company's $1 billion industrial innovation fund, City A.M. reported Thursday. Franziska Bossart, a director of the fund, told the newspaper that the fund has invested in 12 startups in the US and Israel. The...
BMO Reviews North West Company's Q1
BMO Reviews North West Company's Q1
Apr 11, 2024
12:42 PM EDT, 04/11/2024 (MT Newswires) -- North West Company ( NNWWF ) reported in-line Q4/23 operating results, with SSSG below forecast in both Canada and International. Sales growth moderated from a very strong Q3 (+1.4% SSSG); EBITDA +8.2% y/y (in line). BMO's Stephen MacLeod notes there are puts & takes on the near-term outlook, with International headwinds offset by...
Bausch wins US appeal to block Alvogen generic of diarrhea drug
Bausch wins US appeal to block Alvogen generic of diarrhea drug
Apr 11, 2024
April 11 (Reuters) - A U.S. appeals court on Thursday affirmed a decision for Bausch Health ( BHC ) that barred rival drugmaker Alvogen from marketing a proposed generic version of Bausch's diarrhea treatment Xifaxan until 2029. A Delaware federal court had determined that Alvogen subsidiary Norwich Pharmaceuticals' generic would infringe patents owned by Bausch's Salix Pharmaceuticals. It blocked the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved